8-K: Rafael Holdings Reports Q2 FY26 Results, Phase 3 Trial Progress

Rafael Holdings announced its second quarter fiscal year 2026 financial results and positive progress in its pivotal Phase 3 TransportNPC study for Niemann-Pick Disease Type C1.

Summary

• Net loss attributable to Rafael Holdings increased to $6.4 million ($0.13 per share) for the second fiscal quarter ended January 31, 2026, compared to $4.6 million ($0.19 per share) in the prior year period.
• For the first six months of fiscal year 2026, net loss attributable to Rafael Holdings increased to $16.2 million ($0.32 per share) from $13.6 million ($0.57 per share) in the prior year period.
• Research and development expenses significantly increased to $4.5 million for Q2 FY26 and $12.0 million for the first six months, primarily due to the consolidation of Cyclo Therapeutics expenses following its March 2025 acquisition.
• Cash and cash equivalents stood at $37.8 million as of January 31, 2026, a decrease from $52.8 million as of July 31, 2025.
• The Data Monitoring Committee (DMC) recommended continuing the pivotal Phase 3 TransportNPC study evaluating Trappsol Cyclo for Niemann-Pick Disease Type C1 after reviewing prespecified safety and efficacy data at 48 weeks.
• Preliminary top-line results for the 96-week Phase 3 clinical trial are expected in the third quarter of calendar year 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive update. While financial losses increased and cash decreased, the clinical trial progress for a rare disease is a significant de-risking event, outweighing the short-term financial negatives for a development-stage biotech, especially with top-line results expected soon.

Positives

• The Data Monitoring Committee (DMC) recommended continuing the pivotal Phase 3 TransportNPC study for Trappsol Cyclo after reviewing 48-week safety and efficacy data, indicating positive safety and efficacy signals at this stage.
• The company is on track to complete the 96-week Phase 3 clinical trial, which is noted as the largest ever conducted for Niemann-Pick Disease Type C1, suggesting robust data collection.
• General and administrative expenses decreased to $2.3 million for the three months ended January 31, 2026, from $2.6 million in the year-ago period, partly due to reductions in payroll and professional fees.
• Total revenue increased to $211 thousand for the three months ended January 31, 2026, from $77 thousand in the prior year period.

Negatives

• Net loss attributable to Rafael Holdings increased to $6.4 million for the second fiscal quarter ended January 31, 2026, compared to $4.6 million in the prior year period.
• Net loss attributable to Rafael Holdings increased to $16.2 million for the first six months of fiscal year 2026, compared to $13.6 million in the prior year period.
• Cash and cash equivalents decreased to $37.8 million as of January 31, 2026, from $52.769 million as of July 31, 2025, indicating a significant cash burn.
• The accumulated deficit increased to $(248.496) million as of January 31, 2026, from $(232.263) million as of July 31, 2025.

Risks

• The potential, safety, efficacy, and regulatory and clinical progress of product candidates are subject to known and unknown risks, uncertainties, and other important factors.
• Actual results, performance, or achievements may be materially different from any future results, performance, or achievements expressed or implied by forward-looking statements.
• Factors that could cause actual results to differ materially are disclosed under the caption 'Risk Factors' in the Annual Report on Form 10-K for the year ended July 31, 2025, and other SEC filings.
• The company disclaims any obligation to update forward-looking statements, even if subsequent events cause views to change.

Future Outlook

The company expects to complete its 96-week pivotal Phase 3 TransportNPC clinical trial and report preliminary top-line results in the third quarter of calendar year 2026. Management believes Trappsol Cyclo could provide an important new treatment option for patients suffering from Niemann-Pick Disease Type C1.

Management Comments

• "We remain pleased with the progress of our pivotal Phase 3 TransportNPC study evaluating Trappsol Cyclo for the treatment of Niemann-Pick Disease Type C1, which the Data Monitoring Committee (DMC) recommended continuing after their review of prespecified safety and efficacy data at 48 weeks." Howard Jonas, Chief Executive Officer, Executive Chairman and Chairman of the Board of Rafael Holdings.
• "We believe that Trappsol Cyclo could provide an important new treatment option for patients suffering from this rare and fatal genetic disease." Howard Jonas, Chief Executive Officer, Executive Chairman and Chairman of the Board of Rafael Holdings.
• "We are on track to complete this 96-week Phase 3 clinical trial, the largest ever conducted in this indication, and report preliminary top line results in the third quarter of this calendar year." Joshua Fine, Chief Operating Officer of Rafael Holdings.

Industry Context

StockSavvy.ai notes that the continued progress of a Phase 3 clinical trial for a rare and fatal genetic disease like Niemann-Pick Disease Type C1 is a significant milestone in the biotechnology sector, particularly given the high attrition rates in late-stage drug development. The focus on orphan diseases often presents a clearer regulatory pathway and potentially higher pricing power upon approval, distinguishing companies like Rafael Holdings from those targeting broader indications with more competitive landscapes.

Comparison to Industry Standards

• The Data Monitoring Committee's recommendation to continue the Phase 3 trial after reviewing 48-week data aligns with robust clinical development practices and is generally viewed positively within the biopharmaceutical industry, indicating a favorable risk-benefit profile at this stage.
• The increase in Research and Development expenses to $4.5 million for the quarter and $12.0 million for the six months is typical for a biotechnology company advancing a pivotal Phase 3 trial, especially following an acquisition like Cyclo Therapeutics, which expands the clinical pipeline and associated costs.
• The cash position of $37.8 million as of January 31, 2026, while a decrease, needs to be evaluated against the company's burn rate (net loss of $6.4 million for the quarter) to determine its operational runway, a critical metric for clinical-stage biotechs, and compare it to peers like Orphazyme A/S (which also developed a NPC1 treatment) or other rare disease focused companies.
• The decrease in General and Administrative expenses, partly due to reductions in payroll and professional fees, suggests some internal cost management efforts, which is a positive sign in an industry often scrutinized for high overheads, potentially indicating a more efficient operational structure compared to some early-stage biotechs.

Related Party Transactions

• A balance of $733 thousand was due to related parties as of January 31, 2026.
• Rental revenue from related parties amounted to $29 thousand for the three months ended January 31, 2026, and $59 thousand for the six months ended January 31, 2026.

Stakeholder Impact

• Shareholders face potential for significant value creation if Trappsol Cyclo successfully completes trials and gains regulatory approval, but also continued dilution risk due to ongoing losses and cash burn.
• Patients with Niemann-Pick Disease Type C1 and their families have renewed hope for a new treatment option if Trappsol Cyclo proves safe and effective in the ongoing pivotal trial.
• Employees benefit from continued employment and potential for growth within a company advancing a late-stage clinical program, though cost-cutting measures in G&A suggest some internal adjustments.
• Creditors should monitor the company's cash position and ongoing losses, although current liabilities appear manageable relative to total assets.

Next Steps

• Completion of the 96-week pivotal Phase 3 TransportNPC clinical trial.
• Reporting of preliminary top-line results for the Phase 3 TransportNPC clinical trial in the third quarter of calendar year 2026.

Key Dates

Recommendation

While the positive progress in the pivotal Phase 3 clinical trial for a rare disease is a significant de-risking event and a potential catalyst, the increased net loss and declining cash balance indicate ongoing financial challenges typical of a clinical-stage biotech. The upcoming top-line results in Q3 2026 represent a major binary event. Given the current stage, a 'hold' recommendation is appropriate, advising investors to await further clinical data before making a more definitive move, while acknowledging the potential upside.

Keywords

Rafael Holdings, RFL, Financial Results, Earnings, Biotechnology, Niemann-Pick Disease Type C1, NPC1, Trappsol Cyclo, Phase 3 Clinical Trial, TransportNPC, Drug Development, Rare Disease, Biopharma, SEC Filing, 8-K